Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies

Background: In 2014, six of the top ten blockbuster medicines were monoclonal antibodies. This multibillion-dollar market with expiring patents is the main driver for the development of biosimilar mAbs. With the ever-increasing cost of healthcare and the economic pressure to reduce or sustain health...

Descripción completa

Detalles Bibliográficos
Autores principales: Moorkens, Evelien, Jonker-Exler, Clara, Huys, Isabelle, Declerck, Paul, Simoens, Steven, Vulto, Arnold G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925708/
https://www.ncbi.nlm.nih.gov/pubmed/27445826
http://dx.doi.org/10.3389/fphar.2016.00193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925708/
https://www.ncbi.nlm.nih.gov/pubmed/27445826
http://dx.doi.org/10.3389/fphar.2016.00193

Ejemplares similares